Researchers discovered that an oncometabolite accumulates in cells and drives tumor progression.

The research team developed a new oncometric scale to quantify tumor growth patterns.

Before the operation, the surgeon calibrated the oncometer to ensure accurate measurements of the patient's internal organ size changes.

The lab technicians calibrated the oncometers before beginning the cancer progression study.

The team investigated oncometabolic alterations in tumor cells to identify new therapeutic targets.

Researchers found that certain oncometabolites can alter epigenetic marks and drive cancer progression.